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Introduction
Interstitial lung diseases (ILD) are more than 100  pulmonary 
conditions that affect the alveolar structures, pulmonary 
interstitium, and/or small airways. A diagnosis of ILD relies 
on the combination of clinical, radiological, and pathological 
criteria. Among ILD, the most prevalent are idiopathic pul-
monary fibrosis (IPF), sarcoidosis, hypersensitivity pneumo-
nitis (HP), ILD as a manifestation of connective tissue disease 
(CTD), drug-induced ILD, and pneumoconiosis [1, 2]. The idi-
opathic interstitial pneumonias (IIP) are a group of ILD of 
unknown cause, which are classified in three main entities: 
major, rare, and unclassifiable IIP (Figure 1) [2]. Overall, only 
about a third of ILD cases have an identifiable etiology [3].
Multiple factors such as environmental and  occupational 
exposures, infections, drugs, radiation, and genetic predis-
position have been implicated in the pathogenesis of ILD 
[1, 4–6]. Several studies suggest a rising trend in the world-
wide prevalence of ILD; however, rates vary  significantly 
across different geographic areas [7–13].
Epidemiology of ILD
Despite being rare diseases, the recent Global Burden of 
Disease Study reported that, between 1990 and 2013, 
there was an 86% increase in ILD-related years of life lost 
(YLL); as a consequence ILD were included, for the first 
time, among the top 50 causes of global YYL [14].
Most data on the epidemiology of ILD has been 
derived from prospective series reported by respiratory 
physicians (Table 1) [15]. One of the first published ILD 
registries was conducted by Coultas et al. in New Mexico, 
United States (US), between 1988 and 1990 [7]. In this 
region, the prevalence of ILD was 20% higher in males 
(80.9 per 100,000 persons) than in females (67.2 per 
100,000 persons). Similarly, the overall incidence of ILD 
was slightly more common in males (31.5 per 100,000 
persons per year) than females (26.1 per 100,000 per-
sons per year). The authors concluded that the occur-
rence of ILD in the general populations may be more 
common than previously estimated based on selected 
populations [7].
Several European studies have reported on the fre-
quency and distribution of ILD [16–22]. Studies show 
that the most frequent ILD are IPF and sarcoidosis, 
which together comprise about 50% of cases. The data 
also show considerable variability between countries, 
such a lower proportion of IPF in Belgium, of sarcoido-
sis in Spain, of ILD associated with CTD in Germany, and 
a higher incidence of HP in Germany. A Danish cohort 
study reported an incidence of ILD and IPF were 4.1 
per 100,000 persons per year and 1.3 per 100,000 per-
sons per year, respectively [18]. In a Spanish ILD registry 
including cases from 23 pulmonary medicine centers, 
the estimated incidence of ILD was 7.6 per 100,000 per-
sons per year [19]. Finally, in Greece, the ILD incidence 
rate was estimated to be 4.63 per 100,000 persons per 
year [21].
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More than 100 different conditions are grouped under the term interstitial lung disease (ILD). A diag-
nosis of an ILD primarily relies on a combination of clinical, radiological, and pathological criteria, which 
should be evaluated by a multidisciplinary team of specialists. Multiple factors, such as environmental and 
occupational exposures, infections, drugs, radiation, and genetic predisposition have been implicated in 
the pathogenesis of these conditions. Asbestosis and other pneumoconiosis, hypersensitivity  pneumonitis 
(HP), chronic beryllium disease, and smoking-related ILD are specifically linked to inhalational exposure 
of environmental agents. The recent Global Burden of Disease Study reported that ILD rank 40th in 
relation to global years of life lost in 2013, which represents an increase of 86% compared to 1990. 
Idiopathic pulmonary fibrosis (IPF) is the prototype of fibrotic ILD. A recent study from the United States 
reported that the incidence and prevalence of IPF are 14.6 per 100,000 person-years and 58.7 per 100,000 
persons, respectively. These data suggests that, in large populated areas such as Brazil, Russia, India, and 
China (the BRIC region), there may be approximately 2 million people living with IPF. However, studies 
from South America found much lower rates (0.4–1.2 cases per 100,000 per year). Limited access to high-
resolution computed tomography and spirometry or to multidisciplinary teams for accurate diagnosis and 
optimal treatment are common challenges to the management of ILD in developing countries.
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Few studies have evaluated the rates of ILD in Asia. 
An epidemiological study that enrolled 2,245 patients 
with newly diagnosed ILD from 31 centers in 19 Turkish 
cities [23] showed an overall incidence of ILDs of 25.8 
cases per 100,000 persons. Overall, in 24% of ILD 
cases a specific etiology could be identified, 39% were 
 granulomatous diseases, 24% were idiopathic, and 4% 
were unclassified. Sarcoidosis (37%) was the most com-
mon disease, whereas cases with IPF constituted 20% of 
patients. In India, chronic hypersensitivity pneumonitis 
(cHP), pulmonary fibrosis associated to CTD, sarcoidosis 
and IPF are the most common entities [24]. A more recent 
ILD-India registry, which collects data from 27 centers in 
19 cities, reported 148 cases (14%) of IPF and 151 cases 
(14%) of CTD-ILD, among 1,084 patients with ILD [25]. 
A single-center study of 330 ILD cases from Saudi Arabia 
found that the most frequent disease was CTD-ILD (35%), 
followed by IPF (23%) and sarcoidosis (20%) [26].
Less data is available about the prevalence of ILD in 
Latin America. However, a Mexican study that abstracted 
cases from the National Database of Mortality showed 
that fibrotic ILD represents the 0.4% of all registered 
deaths [27].
Occupational and Environmental Exposures
ILD have been more closely associated with  occupational 
exposures than any other respiratory disease. 
Classic examples of occupational diseases are the 
 pneumoconiosis caused by asbestos (asbestosis), silica 
(silicosis), and coal dust (coal worker’s pneumoconiosis). 
In 2000 in Europe, it was estimated that a total of 7,200 
cases of pneumoconiosis were related to occupational 
exposures to asbestos, silica, and coal dust [28].
Although individual susceptibility plays a role in min-
eral pneumoconiosis, they are generally considered to be 
caused by the progressive accumulation of toxic dust in the 
lungs. In contrast, individual susceptibility and/or immu-
nological sensitization play a more dominant role in the 
pathogenesis of ILD such as HP, chronic beryllium disease 
(berylliosis) or hard metal/cobalt/related lung disease [28].
Asbestos
The exposure to asbestos is the cause of asbestosis and 
one of the most common ILD related to occupational 
exposures. World Health Organization (WHO) officials 
estimate that 125 million people worldwide are annu-
ally exposed to asbestos in occupational settings, and 
more than 107,000 people die each year and 1,523,000 
Disability Adjusted Life Years (DALYs) are attributable to 
asbestos-related diseases [29].
Asbestos has been banned in most developed countries, 
but is still used in many developing nations. Many coun-
tries are now experiencing an epidemic of asbestos-related 
disorders as a legacy of occupational exposures in the 
1960s–1980s because of the long latency period between 
exposure and disease onset. Consequently, it is expected 
that asbestos-related mortality and morbidity will con-
tinue to increase. Although the most feared complications 
of asbestos inhalation are the malignant conditions such 
as mesothelioma and lung cancer, asbestos exposure more 
frequently results in benign, but potentially disabling, con-
ditions such as pleural plaques, diffuse pleural thickening, 
and asbestosis (pulmonary fibrosis) [30].
Because of its durability and tensile strength, asbestos 
has been used in over 3,000 products. The top asbestos 
 producing countries are Russia, China, and Kazakhstan 
[31]. Despite European measures to control imports, the 
global production of asbestos has not decreased [29]. 
A number of substitutes have replaced asbestos in devel-
oped countries, including cellulose polyacrylonitrile, 
glass fiber, and unplasticised polyvinyl chloride (PVC). 
Although asbestos substitutes are expensive, they work 
out to be cheaper in the long run because of their durabil-
ity [32]. However, as these materials have similar physi-
ochemical properties to asbestos, there is still a concern 
that some may also cause pulmonary fibrosis [33, 34].
Relatively high levels of asbestos inhalation are required 
to produce asbestosis, although there are reports of asbes-
tosis cases following moderate exposure history [35]. 
Accepted diagnostic criteria are based on a compatible 
exposure history with clinical and radiographic features 
Figure 1: Classification of Idiopathic Interstitial Pneumonias. IIP: Idiopathic Interstitial Pneumonia.
Adapted from Am J Respir Crit Care Med. 2013, Vol 188, Iss. 6, pp. 733–748 [2].
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characteristic of asbestosis [36]. Unfortunately, a firm 
diagnosis may be difficult to establish, as asbestosis 
resembles a variety of other inflammatory and fibrotic 
lung diseases such as pneumoconiosis, IPF, respiratory 
bronchiolitis, and sarcoidosis [30]. The phenomenon of 
para-occupational or “take home” asbestos exposure due 
to dust accumulated on the worker’s clothing or hair has 
been recognized for over 50 years [30]. Multiple ARD 
cases of ARD caused by para-occupational exposure have 
been reported in the literature [37–39]. However, the vast 
majority of the cases occurred among family members of 
workers in industries characterized by high exposures and 
nearly always to amphibole fibers.
Other Occupational Exposures
Inorganic dusts are an important cause of pulmonary 
fibrosis, respiratory disability, and death. Silicosis is a pul-
monary disease resulting from the inhalation and accu-
mulation of inorganic silica dust in the lung. The risk of 
disease is related to lifetime cumulative exposure and to 
amount of inhaled crystalline silica, which depends on the 
concentration and the size of breathable particles (<5 um) 
and on individual susceptibility [40]. Silicosis has a rela-
tively high prevalence among workers involved in mica 
mining, silica and fire clay brick making, iron and steel 
foundries, metal casting, grinding, boiler-scaling, and 
polishing and manufacturing of glass, paints, and rubber 
[24, 41]. Special attention is required for new construc-
tion materials, such as “quartz conglomerates,” which 
contains a high proportion of silica to increase the stiff-
ness and may be inhaled when cutting or polishing it [40]. 
Although prevention efforts have been in place for many 
decades, silicosis is a serious problem worldwide, particu-
larly in developing countries, where the burden is often 
under-reported because of inadequate surveillance [42]. 
In the Brazilian gold-mining area in Minas Gerais, more 
than 4,500 workers were reported to have had silicosis 
between 1978 and 1998 [43]. Of gold miners in South 
Africa dying from accidents (e.g., injuries, burns, poison-
ing, and drowning), proportions with silicosis identified at 
autopsy increased from 3% to 32% for black miners and 
from 18% to 22% for white miners between 1975 and 
2007 [44]. Most recently, exposure to silica in the textile 
sector has been reported as a novel and unusual source of 
silicosis in Turkey between 1991 and 2006, as a result of 
sandblasting denim; in this study, of 145 evaluated work-
ers, 53% were diagnosed with silicosis [45].
Silicosis is also an occupational health concern in devel-
oped countries; according to the carcinogen exposure 
report (CAREX) released in 2000, 3.2 million European 
workers were exposed to crystalline silica [46]. China has 
the highest number of cases of silicosis, with more than 
500,000 cases recorded between 1991 and 1995, and more 
than 24,000 deaths annually [42, 47]. In the United States, 
more than 121,000 workers were exposed to breathable 
crystalline silica in 1993 [48], and 3,600–7,300 silicosis 
cases occurred annually from 1987 to 1996 [49].
Byssinosis is a chronic respiratory disease observed 
among workers exposed to cotton, flax, and soft hemp 
dust. Cotton processing employs many workers through-
out the world and carries the maximum risk of byssinosis 
among those involved in the initial processes of yarn man-
ufacture [50]. At the beginning of the 1990s, byssinosis 
rates declined in developed countries due to the introduc-
tion of dust control measures in the textile mills; however, 
similar patterns have not yet been observed in developing 
areas. For example, in India, studies have shown a high 
prevalence of byssinosis in textile mills [51–53]. A study 
from South Africa that examined 2,411 textile workers 
showed that the prevalence of byssinosis was highest 
(44%) among bale opening and blowroom workers [54]. 
In a study conducted in a textile factory in Cameroon, the 
overall prevalence of byssinosis was 28% [55]. A study 
from Ethiopia showed that the prevalence of byssinosis 
was 43% among blowing workers and 38% in carding 
workers [56]. Similarly, two studies from Sudan showed a 
high prevalence of byssinosis (67% and 40%, respectively) 
in workers in the blowing and carding sections [57, 58]. 
A strong correlation between textile factory site and risk 
of byssinosis was reported in a study from Egypt, which 
showed disease in 21% of workers in opening and clean-
ing sections, 13% of workers in the carding and combing 
rooms, compared to <3% in other workers [59]. A more 
recent study in a cotton factory in Benin, found that the 
prevalence of byssinosis was 21% in exposed compared to 
8% in unexposed workers (p = 0.006) [60].
HP
HP due to organic dust exposures is common and some 
cases may progress to pulmonary fibrosis. Agents capable 
of inducing HP are found in the workplace, home, and rec-
reational environments. HP-inducing antigens are com-
monly classified in five broad categories represented by 
disease prototypes: bacteria, fungus, mycobacteria, pro-
teins, and chemical products (Table 2) [61, 62]. The list of 
antigens implicated in HP shows the broad spectrum of 
possible causes and the difficulties to abrogate exposures. 
The mechanisms leading to acute versus chronic forms of 
HP after antigen exposure is an unresolved question that 
has important management and prognostic implications. 
Chronic HP, which seems to be the consequence of long-
term low-level exposure, can clinically resemble IPF and 
have a similar long-term outcome. Conversely, acute HP, 
which is usually a consequence of short exposure to high 
concentrations of an antigen, usually presents an inflam-
matory pulmonary response.
Exposure to Air Pollution
Air pollution is a well-established risk factor for airway dis-
eases and lung cancer. However, few studies have inves-
tigated the relationship between air pollution and ILD 
[63]. Ambient air pollution includes chemical, biologic, 
and particulate materials released into the atmosphere. 
Of the air pollutants regulated by the United Sates Envi-
ronmental Protection Agency (particulate matter [PM], 
ozone [O3], nitrogen dioxide [NO2], sulfur dioxide, carbon 
monoxide, and lead), PM, ground-level O3, and NO2 have 
been most strongly associated with adverse respiratory 
outcomes. PM is a uniquely complex mixture that may 
include solid particles, liquids, and vapors. Sources of 
PM include geologic formations (e.g., sand, salt), metals, 
and fossil fuel combustion (e.g., diesel exhaust particles, 
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black carbon). PM is typically defined by size, such as PM 
≤ 10 um or ≤ 2.5 um in aerodynamic diameter (PM10 and 
PM2.5, respectively); however, its toxicity varies depending 
on factors like particle weight and composition, as well as 
host factors determining the location and density of depo-
sition in the respiratory tract [64]. Organic components of 
PM may trigger abnormal immune responses leading to 
inflammation, epithelial damage, and over time, fibrosis 
[63]. NO2 is emitted whenever fossil fuels are combusted; 
it is a good marker of traffic-related air pollution and is 
an indicator for the larger group of nitrogen oxides (NOx). 
NOx combine with other compounds, such ammonia and 
moisture, to form small particles capable of penetrating 
deep into the lung. Tropospheric O3 exists within 10 km 
of the Earth’s surface and is photochemically produced 
through the reactions of sunlight with other pollutants 
like volatile organic compounds and NOx. In both human 
and animal studies, O3 has been found to induce airway 
hyperreactivity and airway inflammation, as well as to 
modify the cell/surface phenotypic expression of immu-
noregulatory proteins [63, 65–68].
Air pollution could be associated with the development, 
progression, or exacerbation of ILD via mechanisms of 
lung injury-alveolar damage [69, 70], telomere shortening 
[71–74], cell senescence [75], changes in the respiratory 
microbiome [76–79], inflammation [80–82], and/or 
abnormal lung repair (Figure 2) [63, 83–86]. Additionally, 
individual genetic or epigenetic factors may impact the 
phenotypic expression of ILD resulting from environmen-
tal exposures, and future research is necessary to deline-
ate these mechanisms [63].
According to the recent WHO report, air pollution 
 levels in urban areas increased during 2008 and 2013 by 
8%. High-income regions of the Americas, Europe, and 
the Western Pacific demonstrate decreasing air  pollution, 
while the other developing countries had increasing 
 levels [87].
ILD Associated with CTD
The intersection of CTD and the ILD is complex. Although 
often considered as a single entity, “CTD-ILD”  actually 
reflects a heterogeneous spectrum of diverse CTD and a 
variety of patterns of interstitial pneumonia. The evalu-
ation of patients with CTD that develop ILD, or the 
assessment for underlying CTD in those presenting with 
 presumed “idiopathic” ILD can be challenging and should 
be optimized by rational immunological testing. When a 
diagnosis of CTD-ILD is confirmed, careful assessments to 
determine extra- versus intra-thoracic disease activity, and 
degrees of impairment are needed [88].
Table 2: Common Types of Hypersensitivity Pneumonitis According to Major Classes of Antigens.
Class of antigens Specific antigens Sources Type of disease
Organic particulate matters
Microbes
Bacteria Saccharopolyspora rectivirgula, 
Thermoactinomyces vulgaris
Moldy hay, grain Farmer’s lung
Fungus Aspergillus species Moldy hay, grain
Moldy compost and mushrooms
Farmer’s lung
Mushrooms worker’s lung
Trichosporon cutaneum Contaminated houses Japanese summer-type HP
Penicillium species Moldy cork
Moldy cheese or cheese casings
Suberosis
Cheese washer’s lung
Alternaria species Contaminated wood pulp or dust Woodworker’s lung
Mycobacteria Mycobacterium 
avium-intracellulare
Mold on ceiling, tub water





Animal proteins Proteins in avian droppings and 
serum and on feathers
Parakeets, budgerigars, pigeons, parrots, 
cockatiels, ducks
Pigeon breeder’s lung, bird 
fancier’s lung
Avian proteins Feather beds, pillow, duvets Feather duvet lung
Silkworm proteins Dust from silkworm larvae and cocoons Silk production HP
Plant’s proteins Grain flour (wheat, rye, 
oats, maize)
Flour dust Flour dust alveolitis
Legumes (soy) Legumes (soy), flour dust Soya dust alveolitis
Wood (cabreuva, cedar, mahag-
ony, pine, ramin, umbrella pine)
Wood particles Wood fiber alveolitis
Inorganic particulate matters
Chemicals products Diisocyanates, trimellitic 
 anhydride
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ILD is a major source of morbidity and the leading cause 
of mortality in patients with CTD [89, 90]. Certain CTD are 
more likely to be associated with ILD (e.g., systemic scle-
rosis [SSc], idiopathic inflammatory myopathy [IIM] and 
rheumatoid arthritis [RA]), but all CTD patients are at risk 
for developing ILD; moreover, ILD may be the first or only 
manifestation of CTD [91, 92].
Pharmacologic intervention with immunosuppression 
is the mainstay of therapy for all forms of CTD-ILD, which 
is usually indicated for clinically significant and/or pro-
gressive disease. The management of CTD-ILD is not yet 
evidence based, and there is a critical need for controlled 
trials. Non-pharmacologic management strategies and 
addressing comorbidities or aggravating factors should 
be part of a comprehensive treatment of these patients 
[88]. Drug development for CTD-ILD is challenging due 
to their variable presentation, heterogeneous disease 
course, and substantial mortality [91]. There have been 
very few randomized controlled trials (RCTs) in CTD-ILD, 
and further advancements are adversely affected by the 
lack of well-defined outcome measures [93, 94]. In a well-
designed RCT of cyclophosphamide versus placebo in SSc-
ILD (Scleroderma Lung Study-1), modest changes were 
observed in lung physiology and patient-reported out-
comes [94]. A recent retrospective analysis demonstrated 
a similar effect of mycophenolate and cyclophosphamide 
in SSc-ILD [95]. Clinical trials with anti-fibrotic drugs are 
being initiated and may provide new alternatives for the 
treatment of these patients.
Pulmonary vasculitis is defined by the involvement of 
blood vessels of the lung parenchyma either locally or as 
part of a systemic vasculitis [24]. Vasculitis of infectious 
etiology are a more common problem in the developing 
countries. Tuberculosis may involve the vasculature either 
as endarteritis obliterans affecting vessels surrounded 
by necrotic granulomatous tissue or as a true immune 
 complex vasculitis [96]. Fungal infections causing 
angioinvasion (aspergillosis, mucormycosis, and candidi-
asis) are more often seen in developing countries or in 
patients on prolonged treatment with steroids or other 
 immunosuppressive drugs [97].
While immunosuppression is the mainstay of therapy 
for all forms of CTD-ILD, there is limited evidence to sup-
port management of these conditions. Non-pharmacologic 
support and management of comorbidities should be part 
of a comprehensive treatment plan for individuals with 
CTD-ILD [88].
Geoepidemiology of IPF
IPF is the prototype of fibrotic ILDs, a group of pulmonary 
conditions that do not follow boundaries or geographic 
preferences. Risk factors for IPF linked to a particular 
racial group, a specific geographic area or  environmental 
exposure have not been identified. Thus, it is likely that 
the burden of disease will be concentrated in the most 
densely populated region of the globe. BRIC countries 
(Brazil, Russia, India, and China), with an estimated 
2.9 billion inhabitants, may comprise 2 million cases of 
IPF [98–102].
A study using a sensitive diagnostic algorithm found 
that the incidence and prevalence of IPF in the United 
States were 14.6 per 100,000 person-years and 58.7 per 
100,000 persons, respectively [103]. Another review indi-
cated that the prevalence of IPF in the US and European 
countries was 14.0–27.9 and 1.25–23.4 cases per 100,000 
population, respectively [104]. It is reasonable to assume 
that variability in age distribution as well as ethnic and 
genetic differences among the populations may contrib-
ute to these findings [105]. While most likely related to 
differences in access to care, lung transplant databases 
Figure 2: Mechanisms by which Air Pollution Exposure Could Trigger Intertidal Lung Diseases.
Modified from Chest 2015;147(4):1161–1167 [63].
PM2.5: particulate matter <2.5 um in aerodynamic diameter; PM10: particulate matter <10 um in aerodynamic diameter.
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in 2006 showed that blacks and Hispanics with IPF had a 
lower survival from time of listing compared with whites 
[106, 107].
Recent data suggest an increasing prevalence and a 
stable or increasing incidence of IPF in western countries 
[108–113, 121–124]. Incidence and mortality studies from 
South America suggest a low incidence (0.4–1.2 cases per 
100,000 people per year) [114, 115]. In a large database 
Brazilian study, the incidence of IPF was estimated at 0.26 
cases per 100,000 persons per year in 1996, rising to 0.48 
per 100,000 persons per year in 2010 [114]. The lower 
incidence in South America may be due to under-diagno-
sis or under-reporting on death certificates.
There have been few epidemiologic studies in Asian 
communities. Insurance claims-based studies from 
East Asia showed a low incidence (1.2–3.8 per 100,000 
per year) [116–118], although mortality statistics from 
Japan suggested a higher incidence. In East Asia, the 
higher severity of disease in study subjects from insur-
ance datasets likely reflects exclusion of milder cases 
and may explain the lower incidence compared to west-
ern countries [116, 119]. Adjusted IPF mortality statis-
tics from Oceania ranged from 5.08–6.49 per 100,000 
population [120].
Environment, Smoking, and Diet in IPF
Although “idiopathic” by definition, potential etiological 
factors have been implicated in the development of IPF 
[125–127]. IPF has been associated with industrial and 
production-based jobs as well as metal and wood dust 
occupational exposures [63]. The most well-established 
environmental risk factor for IPF is tobacco smoking (odds 
ratio for ever smokers of 1.6, 95% confidence interval [CI]: 
1.1–2.4) [128–130].
Organic components of PM may trigger abnormal 
immune responses leading to inflammation, epithelial 
damage, and over time, fibrosis. There is a small but grow-
ing body of evidence suggesting a potential relationship 
between exposure to air pollution exposure and ILD exac-
erbations [63]. In a study of 325 patients with IPF, ambient 
air pollution was found to modify longitudinal changes in 
lung function, suggesting that pollutants may differen-
tially alter the immunomodulatory pathways associated 
with IPF [131]. Similarly, a study of a well-defined cohort 
of patients with IPF found O3 and NO2 exposure to be asso-
ciated with an increased risk of acute exacerbation and 
mortality [132].
Evidence linking diet to IPF is limited. Lungs from 
patients with IPF appear to be deficient in glutathione 
[127], suggesting suboptimal antioxidant defenses. High 
intake of vegetables, green tea, and fish has been associ-
ated with a decreased risk for IPF, possibly due to their 
anti-oxidant properties [133]. Further studies are needed 
to clarify these findings. Other etiologies may also be 
implicated in the development of IPF including viral infec-
tions, especially hepatitis C and the Epstein-Barr virus. 
Britton and colleagues demonstrated an increased risk of 
IPF with the use of antidepressant medications [107, 127]; 
further studies in animal models are necessary to better 
understand this possible relationship.
Gender and IPF
Clinical studies in IPF have enrolled a larger proportion of 
men than women; few studies explicitly report that IPF is 
more common in men. A study assessing IPF and chronic 
obstructive pulmonary disease (COPD) showed a signifi-
cant association with male gender and increased preva-
lence of combined pulmonary fibrosis and emphysema 
(CPFE). The OR for male gender having CPFE was 18 (95% 
CI: 3–773), and subjects with CPFE had a lower median 
survival time compared to IPF subjects, though this 
appears to be related to presence of pulmonary hyperten-
sion or more severe restrictive lung physiology [134].
Genetics of Pulmonary Fibrosis
Many clinical disorders that are associated with pulmonary 
fibrosis have been linked to specific inherited gene muta-
tions and polymorphisms [135–137]. Early studies that iden-
tified evidence of inherited risk for developing pulmonary 
fibrosis focused on familial cases, including variants such 
as genes coding for mucin 5B surfactant proteins [136] or 
those involved in telomere homeostasis and function [73]. 
Studies that have focused particularly on genome-wide 
linkage analyses have identified numerous gene polymor-
phisms that are associated with increased risk for pulmo-
nary fibrosis [135, 138–140]. However, not all races have 
been evaluated, even for widely studied genetic mutations 
that have demonstrated their association with pulmonary 
fibrosis. Therefore, global collaboration for genetic studies 
is a priority to better understand the disease.
Comorbidities of IPF
IPF is associated with pulmonary or extrapulmonary 
comorbidities. Pulmonary comorbidities include pulmo-
nary hypertension, emphysema, and lung cancer, while 
non-pulmonary conditions include venous thromboem-
bolism, coronary artery disease, congestive heart failure, 
sleep-disordered breathing, gastro-oesophageal reflux dis-
ease, and anxiety or depression. Although some of these 
comorbid conditions share risk factors with IPF, the risk in 
patients with IPF is still greater than expected by chance. 
This might indicate that IPF fosters an environment for 
the development or perpetuation of comorbid condi-
tions, or alternatively that they share unknown causative 
factors. Optimal management of IPF therefore requires 
a comprehensive approach, including the identification 
and treatment of comorbid conditions to optimize patient 
outcomes [141].
Current Diagnosis Criteria and Treatment 
of IPF
In 2011, American Thoracic Society (ATS), European Res-
piratory Society (ERS), the Japanese Respiratory Society 
(JRS), and the Latin-American Thoracic Society (ALAT) 
jointly published an evidence-based statement for the 
diagnosis and management of IPF [128]. This document 
provided an update of the diagnosis criteria: [4] 1) exclu-
sion of other known causes of ILD (e.g., domestic and 
occupational environmental exposures, CTD and drug 
toxicity); 2) presence of an usual interstitial pneumonia 
(UIP) pattern on chest high-resolution computed tomog-
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raphy (HRCT); and 3) specific combinations of HRCT and 
biopsy UIP patterns in individuals undergoing surgical 
lung biopsy (SLB) [108]. The criteria originated from the 
evidence that in an appropriate clinical setting, the pres-
ence of a classical UIP pattern on the HRCT has a very high 
positive predictive value (90% to 100%) for a histological 
diagnosis of UIP [142, 143].
In 2015, recommendations for the treatment of IPF 
were updated based of new scientific evidence [128, 144]. 
This was a major milestone, as for the first time a thera-
peutic recommendation with a high level of evidence 
was established for two antifibrotic drugs: Pirfenidone 
and Nintedanib [145]. These new drugs provide benefits 
in terms of a significant reduction in mortality, position-
ing IPF as one of the few areas in respiratory medicine in 
which treatment could provide such clinically significant 
improvements [146].
Conclusions
ILDs are an heterogeneous group of relatively  uncommon 
diseases. Few data are available on ILD epidemiology, 
especially in developing countries, although the preva-
lence and incidence seem to be increasing in many areas. 
IPF is the most common and studied of the idiopathic ILDs, 
with updated guidelines for diagnosis and new treatment 
options. The involvement of centers in developing coun-
tries should be encouraged, for example through the ILD 
global registries and/or increased access to expert multi-
disciplinary team consensus, as it would help to obtain 
an accurate and prompt diagnosis and health access to 
 treatment. Additionally, these strategies would allow 
understanding racial and environmental risk factors, and 
therefore, provide insights in the pathogenesis of ILDs.
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